Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment

Damien Bresson, Georgia Fousteri, Yulia Manenkova, Michael Croft, Matthias von Herrath

Research output: Contribution to journalArticle

Abstract

Antigen-specific therapies are possibly the safest approach to prevent type 1 diabetes (T1D). However their clinical translation has yielded poor results and greater efforts need to be put into the development of novel strategies to ameliorate their clinical outcome. OX40 is a costimulatory molecule expressed by T cells after antigen recognition and has been implicated in the control effector but also regulatory T cells (Tregs) function in vivo. The activity of OX40 signal on Tregs function has been controversial. In this context we investigated whether an anti-OX40 agonist antibody treatment can ameliorate antigen-specific immune intervention for the prevention of T1D. We show that treatment of non-obese diabetic (NOD) mice with an OX40 agonistic antibody (OX86) reduced type 1 diabetes (T1D) incidence by inducing both CD4 +CD25 +Foxp3 + Tregs and CD4 +Foxp3 - T cells expressing the latency-associated peptide (LAP). These OX86-induced CD4 +Foxp3 -LAP + T cells also demonstrated suppressive activity in vitro. A significant increase in protection was observed when OX86 was combined with insulin B9:23 (insB9:23) peptide immunizations. Synergy resulted from an expansion of IL-10-expressing insB9:23-reactive Tregs which augmented the proportion of CD4 + T cells with in vivo suppressive activity. Consequently, CD4 + T cells purified from OX86/insB9:23 combination treatment prevented T1D development when adoptively transferred into recipient mice. These findings suggest that the requirement for OX40 signaling by antigen-induced Tregs can be dominant over its well-documented need for effector memory cell function and may have potentially important implications for improving the clinical translation of antigen-specific prevention of T1D and possibly other autoimmune disorders.

Original languageEnglish
Pages (from-to)342-351
Number of pages10
JournalJournal of Autoimmunity
Volume37
Issue number4
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Inbred NOD Mouse
Type 1 Diabetes Mellitus
T-Lymphocytes
Antigens
Insulin
Peptide T
Therapeutics
Antibodies
Regulatory T-Lymphocytes
Interleukin-10
Immunization
Peptides
Incidence

Keywords

  • Immunotherapy
  • Insulin B9-23 peptide
  • OX40
  • Regulatory T cells (Tregs)
  • Tolerance
  • Type 1 diabetes (T1D)

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. / Bresson, Damien; Fousteri, Georgia; Manenkova, Yulia; Croft, Michael; von Herrath, Matthias.

In: Journal of Autoimmunity, Vol. 37, No. 4, 12.2011, p. 342-351.

Research output: Contribution to journalArticle

Bresson, Damien ; Fousteri, Georgia ; Manenkova, Yulia ; Croft, Michael ; von Herrath, Matthias. / Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. In: Journal of Autoimmunity. 2011 ; Vol. 37, No. 4. pp. 342-351.
@article{863069652e224622bd59f8244d5b555a,
title = "Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment",
abstract = "Antigen-specific therapies are possibly the safest approach to prevent type 1 diabetes (T1D). However their clinical translation has yielded poor results and greater efforts need to be put into the development of novel strategies to ameliorate their clinical outcome. OX40 is a costimulatory molecule expressed by T cells after antigen recognition and has been implicated in the control effector but also regulatory T cells (Tregs) function in vivo. The activity of OX40 signal on Tregs function has been controversial. In this context we investigated whether an anti-OX40 agonist antibody treatment can ameliorate antigen-specific immune intervention for the prevention of T1D. We show that treatment of non-obese diabetic (NOD) mice with an OX40 agonistic antibody (OX86) reduced type 1 diabetes (T1D) incidence by inducing both CD4 +CD25 +Foxp3 + Tregs and CD4 +Foxp3 - T cells expressing the latency-associated peptide (LAP). These OX86-induced CD4 +Foxp3 -LAP + T cells also demonstrated suppressive activity in vitro. A significant increase in protection was observed when OX86 was combined with insulin B9:23 (insB9:23) peptide immunizations. Synergy resulted from an expansion of IL-10-expressing insB9:23-reactive Tregs which augmented the proportion of CD4 + T cells with in vivo suppressive activity. Consequently, CD4 + T cells purified from OX86/insB9:23 combination treatment prevented T1D development when adoptively transferred into recipient mice. These findings suggest that the requirement for OX40 signaling by antigen-induced Tregs can be dominant over its well-documented need for effector memory cell function and may have potentially important implications for improving the clinical translation of antigen-specific prevention of T1D and possibly other autoimmune disorders.",
keywords = "Immunotherapy, Insulin B9-23 peptide, OX40, Regulatory T cells (Tregs), Tolerance, Type 1 diabetes (T1D)",
author = "Damien Bresson and Georgia Fousteri and Yulia Manenkova and Michael Croft and {von Herrath}, Matthias",
year = "2011",
month = "12",
doi = "10.1016/j.jaut.2011.10.001",
language = "English",
volume = "37",
pages = "342--351",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment

AU - Bresson, Damien

AU - Fousteri, Georgia

AU - Manenkova, Yulia

AU - Croft, Michael

AU - von Herrath, Matthias

PY - 2011/12

Y1 - 2011/12

N2 - Antigen-specific therapies are possibly the safest approach to prevent type 1 diabetes (T1D). However their clinical translation has yielded poor results and greater efforts need to be put into the development of novel strategies to ameliorate their clinical outcome. OX40 is a costimulatory molecule expressed by T cells after antigen recognition and has been implicated in the control effector but also regulatory T cells (Tregs) function in vivo. The activity of OX40 signal on Tregs function has been controversial. In this context we investigated whether an anti-OX40 agonist antibody treatment can ameliorate antigen-specific immune intervention for the prevention of T1D. We show that treatment of non-obese diabetic (NOD) mice with an OX40 agonistic antibody (OX86) reduced type 1 diabetes (T1D) incidence by inducing both CD4 +CD25 +Foxp3 + Tregs and CD4 +Foxp3 - T cells expressing the latency-associated peptide (LAP). These OX86-induced CD4 +Foxp3 -LAP + T cells also demonstrated suppressive activity in vitro. A significant increase in protection was observed when OX86 was combined with insulin B9:23 (insB9:23) peptide immunizations. Synergy resulted from an expansion of IL-10-expressing insB9:23-reactive Tregs which augmented the proportion of CD4 + T cells with in vivo suppressive activity. Consequently, CD4 + T cells purified from OX86/insB9:23 combination treatment prevented T1D development when adoptively transferred into recipient mice. These findings suggest that the requirement for OX40 signaling by antigen-induced Tregs can be dominant over its well-documented need for effector memory cell function and may have potentially important implications for improving the clinical translation of antigen-specific prevention of T1D and possibly other autoimmune disorders.

AB - Antigen-specific therapies are possibly the safest approach to prevent type 1 diabetes (T1D). However their clinical translation has yielded poor results and greater efforts need to be put into the development of novel strategies to ameliorate their clinical outcome. OX40 is a costimulatory molecule expressed by T cells after antigen recognition and has been implicated in the control effector but also regulatory T cells (Tregs) function in vivo. The activity of OX40 signal on Tregs function has been controversial. In this context we investigated whether an anti-OX40 agonist antibody treatment can ameliorate antigen-specific immune intervention for the prevention of T1D. We show that treatment of non-obese diabetic (NOD) mice with an OX40 agonistic antibody (OX86) reduced type 1 diabetes (T1D) incidence by inducing both CD4 +CD25 +Foxp3 + Tregs and CD4 +Foxp3 - T cells expressing the latency-associated peptide (LAP). These OX86-induced CD4 +Foxp3 -LAP + T cells also demonstrated suppressive activity in vitro. A significant increase in protection was observed when OX86 was combined with insulin B9:23 (insB9:23) peptide immunizations. Synergy resulted from an expansion of IL-10-expressing insB9:23-reactive Tregs which augmented the proportion of CD4 + T cells with in vivo suppressive activity. Consequently, CD4 + T cells purified from OX86/insB9:23 combination treatment prevented T1D development when adoptively transferred into recipient mice. These findings suggest that the requirement for OX40 signaling by antigen-induced Tregs can be dominant over its well-documented need for effector memory cell function and may have potentially important implications for improving the clinical translation of antigen-specific prevention of T1D and possibly other autoimmune disorders.

KW - Immunotherapy

KW - Insulin B9-23 peptide

KW - OX40

KW - Regulatory T cells (Tregs)

KW - Tolerance

KW - Type 1 diabetes (T1D)

UR - http://www.scopus.com/inward/record.url?scp=82955247641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955247641&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2011.10.001

DO - 10.1016/j.jaut.2011.10.001

M3 - Article

C2 - 22063316

AN - SCOPUS:82955247641

VL - 37

SP - 342

EP - 351

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 4

ER -